Treatment outcomes of vulvar and vaginal melanoma at an NCCN institution between 1993 and 2021.

ABSTRACT:

Background

Vulvar melanoma and vaginal melanoma are rare and difficult to treat. We describe the last three decades in a cohort predominantly treated surgically with adjuvant therapy.

Methods

All new patients between 1993 and 2021 followed until 2024. Collection of demographic and oncologic data allowed comparisons and Kaplan-Meier method was used to evaluate overall survival (OS) and progression free survival (PFS) stratified by adjuvant therapy type, diagnosis before and after 2011, and between vulvar and vaginal melanomas.

Results

Consultation for 63/72 patients (87.5 %) were for primary treatment. Most patients had vulvar melanoma (50/72, 69.4 %), received surgery (65/72, 90.3 %), and adjuvant treatment (40/72, 55.6 %) with immunotherapy, chemotherapy, and/or targ

SUBMITTER: Ostby SA 

PROVIDER: S-EPMC11379566 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature